XC
XCY.F OPKO Health Inc
- Market cap
- EUR 1.10B
- P/E
- -
- P/B
- 1.12x
- ROE
- -14.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is XCY.F undervalued?
Graham numberThe Graham number of OPKO Health Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
OPKO Health Inc fundamental analysis
No fundamental analysis for OPKO Health Inc yet.
OPKO Health Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About OPKO Health Inc
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecifi…
Full company profileOPKO Health Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
OPKO Health Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.22B | 1.07B | 990M | 902M | 1.44B | 1.77B | 1.00B | 863M | 713M | 607M | 471M |
| Gross Profit | 610M | 447M | 386M | 329M | 541M | 582M | 288M | 318M | 219M | 206M | 224M |
| Operating Income | -56.3M | -283M | -166M | -197M | 53.7M | -14.5M | -246M | -158M | -274M | -219M | -143M |
| EBITDA | - | -167M | -68.0M | -190M | 156M | 35.8M | -158M | -65.5M | 135M | -41.3M | -12.2M |
| Net Income | -25.1M | -309M | -153M | -315M | 30.6M | -30.1M | -328M | -189M | -53.2M | -226M | -156M |
| EPS | - | -0.55 | -0.26 | -0.47 | 0.05 | -0.04 | -0.43 | -0.24 | -0.08 | -0.30 | -0.21 |
| Balance Sheet | |||||||||||
| Total Assets | 2.77B | 2.58B | 2.45B | 2.31B | 2.47B | 2.40B | 2.17B | 2.01B | 2.20B | 1.93B | 1.88B |
| Total Liabilities | 675M | 699M | 660M | 695M | 802M | 715M | 606M | 622M | 835M | 664M | 764M |
| Shareholders' Equity | 2.09B | 1.89B | 1.79B | 1.61B | 1.67B | 1.69B | 1.56B | 1.39B | 1.37B | 1.27B | 1.12B |
| Cash & Short-term Investments | 169M | 91.5M | 96.5M | 85.5M | 72.2M | 135M | 153M | 95.9M | 432M | 369M | 390M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 32.0M | -92.1M | -109M | -173M | 39.5M | 38.3M | -95.2M | -28.2M | -183M | -179M | -132M |
| Capital Expenditure | 23.5M | 46.5M | 27.9M | 12.7M | 33.7M | 32.2M | 24.6M | 16.3M | 25.0M | 12.3M | 10.8M |
| Free Cash Flow | - | -139M | -137M | -185M | 5.79M | 6.18M | -120M | -44.5M | -208M | -191M | -143M |
| Ratios | |||||||||||
| ROE | -1.2% | -16.4% | -8.5% | -19.5% | 1.8% | -1.8% | -21.0% | -13.6% | -3.9% | -17.8% | -14.0% |
| ROA | -0.9% | -12.0% | -6.2% | -13.6% | 1.2% | -1.3% | -15.2% | -9.4% | -2.4% | -11.7% | -8.3% |
| Net Profit Margin | -2.1% | -28.9% | -15.5% | -34.9% | 2.1% | -1.7% | -32.7% | -21.9% | -7.5% | -37.2% | -33.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
OPKO Health Inc dividends
OPKO Health Inc has not paid dividends in the last 9 fiscal years.
Who owns OPKO Health Inc
- Insiders 50.78%
- Institutions 27.87%
- Public & others 21.35%
- Shares outstanding 743M
- Free float 320M
OPKO Health Inc company profile
- Company name
- OPKO Health Inc
- Ticker
- XCY.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,275
- Fiscal year end
- December
- Address
- 4400 Biscayne Boulevard, Miami, FL, United States, 33137
- Phone
- 305 575 4100
- Website
- opko.com
About OPKO Health Inc
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.
OPKO Health Inc management
10- Dr. Phillip Frost M.D., Ph.D.Chairman of the Board & CEO · born 1936
- Dr. Jane H. Hsiao M.B.A., Ph.D.Vice Chairman of the Board & Chief Technical Officer · born 1947
- Dr. Elias Adam Zerhouni M.D.President & Vice Chairman of the Board · born 1951
- Mr. Adam E. LogalSenior VP, CFO, Chief Accounting Officer & Treasurer · born 1978
- Mr. Steven D. Rubin Esq., J.D.Executive VP of Administration & Director · born 1960
- Dr. Akhtar Ashfaq FACP, FASN, M.D.Senior Vice President of Clinical Research & Development and Medical Affairs - Opko Renal
- Dr. Gary J. Nabel M.D., Ph.D.Chief Innovation Officer & Director · born 1954
- Mr. Giovanni Abbadessa M.D., Ph.D.Chief Medical Officer of ModeX
- Dr. John R. Mascola M.D.Chief Scientific Officer of ModeX
- Mr. Gene YauHead of Business Development